Trials / Completed
CompletedNCT03009019
Efficacy, Tolerability, and Safety of DFN-15
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 631 (actual)
- Sponsor
- BioDelivery Sciences International · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DFN-15 Active | |
| OTHER | DFN-15 Placebo |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2017-11-01
- Completion
- 2019-05-01
- First posted
- 2017-01-04
- Last updated
- 2023-01-10
- Results posted
- 2023-01-10
Locations
43 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03009019. Inclusion in this directory is not an endorsement.